BrUOG 413

Adjuvant Trastuzumab Deruxtecan (Enhertu) + Nivolumab For Patients Who Are Disease Free After Completion of Trimodality Treatment For HER-2expressing Esophagogastric cancer.
Status:

Open

Trial Type:

Contact:

Dr. Howard Safran
hsafran@lifespan.org